JSB Market Research: PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022
During the forecast period from 2012-2022, the growth of the ulcerative colitis market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. See More: http://goo.gl/tW6DQL
During the forecast period from 2012-2022, the growth of the ulcerative colitis market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada.
See More: http://goo.gl/tW6DQL
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
5.11 India 108<br />
6 Competitive Assessment 110<br />
6.1 Overview 110<br />
6.2 Strategic Competi<strong>to</strong>r Assessment 111<br />
6.3 Product Profiles - Major Br<strong>and</strong>s 113<br />
6.3.1 Remicade (infliximab) 113<br />
6.3.2 Humira (adalimumab) 121<br />
6.3.3 Simponi (golimumab) 127<br />
6.3.4 Apriso (mesalamine) 131<br />
6.3.5 Asacol HD (mesalamine) 137<br />
6.3.6 Lialda (mesalamine) 142<br />
6.3.7 Pentasa (mesalamine) 146<br />
6.3.8 Colazal (balsazide disodium) 150<br />
6.3.9 Giazo (balsalazide disodium) 154<br />
6.3.10 sfRowasa (mesalamine) 158<br />
6.3.11 Uceris (budesonide) 161<br />
6.3.12 Other <strong>Drug</strong> Classes Used in the Treatment of UC 165<br />
6.4 Biosimilars 166<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Change language